U.S. replaces director of agency overseeing COVID-19 vaccines, drugs [Reuters]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Reuters
U.S. replaces director of agency overseeing COVID-19 vaccines, drugs CHICAGO (Reuters) - The U.S. Department of Health and Human Services said on Tuesday it has replaced Rick Bright as director of a key U.S. agency charged with developing drugs and vaccines for COVID-19. Bright, who was director of the Biomedical Advanced Research and Development Authority (BARDA) since 2016, has been moved to a new public-private partnership under the National Institutes of Health announced last week, according to a Health and Human Services representative. BARDA serves under the HHS Office of the Assistant Secretary for Preparedness and Response. Under Bright’s leadership, BARDA recently announced nearly $1 billion in support of vaccine manufacturing efforts by Moderna and Johnson & Johnson. Bright, an expert in vaccines and therapeutics, will be replaced by Gary Disbrow, his former deputy, who will serve as acting director of BARDA. The change was first reported by STAT news.
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna (NASDAQ:MRNA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Moderna (NASDAQ:MRNA) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Moderna (NASDAQ:MRNA) was given a new $18.00 price target on by analysts at UBS Group AG.MarketBeat
- Moderna (NASDAQ:MRNA) had its price target raised by analysts at Leerink Partners from $15.00 to $18.00. They now have an "underperform" rating on the stock.MarketBeat
- Moderna (NASDAQ:MRNA) had its price target lowered by analysts at Royal Bank Of Canada from $28.00 to $25.00. They now have a "sector perform" rating on the stock.MarketBeat
MRNA
Earnings
- 11/6/25 - Beat
MRNA
Sec Filings
- 12/2/25 - Form 4
- 12/2/25 - Form 4
- 12/1/25 - Form 4
- MRNA's page on the SEC website